Heteromerization of μ-opioid receptor and cholecystokinin B receptor through the third transmembrane domain of the μ-opioid receptor contributes to the anti-opioid effects of cholecystokinin octapeptide

Activation of the cholecystokinin type B receptor (CCKBR) by cholecystokinin octapeptide (CCK-8) inhibits opioid analgesia. Chronic opiate treatment leads to an increase in the CCK-8 concentration and thus enhances the antagonism of CCK-8 against opioid analgesia; the underlying molecular mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yin, Li, Qian, He, Qi-Hua, Han, Ji-Sheng, Su, Li, Wan, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960647/
https://www.ncbi.nlm.nih.gov/pubmed/29780163
http://dx.doi.org/10.1038/s12276-018-0090-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960647/
https://www.ncbi.nlm.nih.gov/pubmed/29780163
http://dx.doi.org/10.1038/s12276-018-0090-5

Ejemplares similares